N-dichloromethylpyrrolidinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-dichloromethylpyrrolidinone
• 英文别名: 1-(Dichloromethyl)pyrrolidin-2-one
• 化学式: C₅H₇Cl₂NO
• 分子量: 168.023
• InChiKey: RWJDWTFJXPAYPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-dichloromethylpyrrolidinone 、 Ru(η6-p.cymene)(η4-cycloocta-1,5-diene) 、 三环己基膦 以 苯 为溶剂， 反应 3.0h， 以48%的产率得到
  参考文献：
  名称：

  PROCESS FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS

  摘要：

  公开号：

  EP1431302B1

文献信息

• Acylated Exendin-4 Compounds
  申请人：Lau Jesper

  公开号：US20090318353A1

  公开（公告）日：2009-12-24

  This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.

  本发明提供了新的治疗性肽，即新的长效Exendin-4化合物、药物组合物及其用途。
• Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
  申请人：Abraxis BioScience, LLC

  公开号：EP2359859A1

  公开（公告）日：2011-08-24

  The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

  本发明涉及一种药物组合物，它包括一种药剂和一种药学上可接受的载体，该载体包括一种蛋白质，例如人血清白蛋白和/或去铁胺。人血清白蛋白的含量可有效减少与服用药物组合物相关的一种或多种副作用。本发明还提供了减少施用药物组合物的一种或多种副作用的方法、抑制药物组合物中微生物生长和氧化的方法，以及增强药物与细胞的转运和结合的方法。
• Albumin-binding derivatives of GLP-1
  申请人：NOVO NORDISK A/S

  公开号：EP2932981A2

  公开（公告）日：2015-10-21

  Novel polypeptide derivatives having protracted profile of action

  具有持久作用特征的新型多肽衍生物
• Process for synthesis of organometallic compounds
  申请人：Hiraike Hiroshi

  公开号：US20060030723A1

  公开（公告）日：2006-02-09

  A method for synthesizing an organometallic compound, which is usefully utilized as a catalyst for manufacturing polyolefins by ring-opening metathesis polymerization of an olefin having strain in a molecule such as dicyclopentadiene or synthesizing epothilones by ring-dosing metathesis reaction, by an efficient and low cost synthesis method using a starting material which is easily available due to relatively simple chemical structure, and further without any possibility of coexistence of a vinylhetero compound or a vinyl compound exchanged which tends to accompany as an impurity in the system in conventional methods, characterized by reacting a starting material comprising a zero-valent transition metal complex (A) or a polyvalent transition metal complex (A′), a compound (B) or (B′) shown by the following general formula (1) or (4), respectively, and a neutral ligand (C) or (C′), in one step under non-reducing condition or reducing condition. R 1 Y 1 CR 2 X 1 2 (1) R 4 Y 2 CR 5 X 2 2 (4)

  一种有机金属化合物的合成方法，该化合物可用作催化剂，通过分子中具有应变性的烯烃（如二环戊二烯）的开环偏聚合反应制造聚烯烃，或通过环配料偏聚合反应合成表噻吩酮，该方法采用高效、低成本的合成方法，使用的起始原料由于化学结构相对简单而易于获得、在传统方法中，乙烯基杂环化合物或交换的乙烯基化合物往往作为杂质存在于体系中，而本发明不存在这种可能性，其特征在于：使包含零价过渡金属络合物（A）或多价过渡金属络合物（A′）的起始原料发生反应、分别如下通式(1)或(4)所示的化合物(B)或(B′)和中性配体(C)或(C′)，在非还原条件或还原条件下一步反应。 R 1 Y 1 CR 2 X 1 2 (1) R 4 Y 2 CR 5 X 2 2 (4)
• ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL
  申请人：SEKISUI CHEMICAL CO., LTD.

  公开号：EP1604964B1

  公开（公告）日：2009-06-10